# TWB-103 for Adult Patients With Split-Thickness Skin Graft Donor Site Wounds

> **NCT02737748** · PHASE1,PHASE2 · COMPLETED · sponsor: **Transwell Biotech Co., Ltd.** · enrollment: 48 (actual)

## Conditions studied

- Donor Site Complication

## Interventions

- **DRUG:** TWB-103 Group
- **DRUG:** Placebo Group

## Key facts

- **NCT ID:** NCT02737748
- **Lead sponsor:** Transwell Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-06
- **Primary completion:** 2021-05-07
- **Final completion:** 2021-05-07
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2023-07-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02737748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02737748, "TWB-103 for Adult Patients With Split-Thickness Skin Graft Donor Site Wounds". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02737748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*